Role of RAF/MEK/ERK pathway, p-STAT-3 and Mcl-1 in sorafenib activity in human pancreatic cancer cell lines

Journal of Cellular Physiology

Volumn 220, Issue 1, 2009, Pages 214-221

  Ulivi, Paola ^a   Arienti, Chiara ^a   Amadori, Dino ^a   Fabbri, Francesco ^a   Carloni, Silvia ^a   Tesei, Anna ^a   Vannini, Ivan ^a   Silvestrini, Rosella ^a   Zoli, Wainer ^a  

^a DEPARTMENT OF MEDICAL ONCOLOGY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; BIOLOGICAL MARKER; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE KINASE; PHOSPHOPROTEIN; PROTEIN KINASE B; PROTEIN MCL 1; RAF PROTEIN; RAS PROTEIN; SMALL INTERFERING RNA; SORAFENIB; STAT3 PROTEIN; ANTINEOPLASTIC AGENT; BENZENESULFONIC ACID DERIVATIVE; MESSENGER RNA; MYELOID CELL LEUKEMIA SEQUENCE 1 PROTEIN; PROTEIN BCL 2; PROTEIN KINASE INHIBITOR; PYRIDINE DERIVATIVE; STAT3 PROTEIN, HUMAN;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER RESISTANCE; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOWN REGULATION; DRUG MECHANISM; DRUG SENSITIVITY; ENZYME INHIBITION; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; ONCOGENE K RAS; PANCREAS ADENOCARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; UPREGULATION; DOSE RESPONSE; DRUG EFFECT; ENZYMOLOGY; GENETICS; METABOLISM; ONCOGENE RAS; PANCREAS TUMOR; PATHOLOGY; PHOSPHORYLATION; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TIME; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BENZENESULFONATES; CELL LINE, TUMOR; CELL PROLIFERATION; DOSE-RESPONSE RELATIONSHIP, DRUG; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; GENES, RAS; HUMANS; MAP KINASE SIGNALING SYSTEM; MITOGEN-ACTIVATED PROTEIN KINASE KINASES; PANCREATIC NEOPLASMS; PHOSPHORYLATION; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-AKT; PROTO-ONCOGENE PROTEINS C-BCL-2; PYRIDINES; RAF KINASES; RNA INTERFERENCE; RNA, MESSENGER; RNA, SMALL INTERFERING; STAT3 TRANSCRIPTION FACTOR; TIME FACTORS;

EID: 65549142508     PISSN: 00219541     EISSN: None     Source Type: Journal    
DOI: 10.1002/jcp.21753     Document Type: Article

References (26)

1. Bardeesy N, DePinho RA. 2002. Pancreatic cancer biology and genetics. Nat Rev Cancer 2:897-909.
2. Boucher MJ, Morisset J, Vachon PH, Reed JC, Laine J, Rivard N. 2000. MEK/ERK signaling pathway regulates the expression of Bcl-2, Bcl-X(L), and Mcl-1 and promotes survival of human pancreatic cancer cells. J Cell Biochem 79:355-369.
3. Brunner TB, Hahn SM, Gupta AK, Muschel RJ, McKenna WG, Bernhard EJ. 2003. Farnesyltransferase inhibitors: An overview of the results of preclinical and clinical investigations. Cancer Res 63:5656-5668.
4. Delgado JS, Mustafi R, Yee J, Cerda S, Chumsangsri A, Dougherty U, Lichtenstein L, Fichera A, Bissonnette M. 2008. Sorafenib triggers antiproliferative and pro-apoptotic signals in human esophageal adenocarcinoma cells. Dig Dis Sci 53:3055-3064.
5. Gysin S, Lee SH, Dean NM, McMahon M. 2005. Pharmacologic inhibition of RAF!MEK!ERK signaling elicits pancreatic cancer cell cycle arrest through induced expression of p27Kip1. Cancer Res 65:4870-4880.
6. Haura EB, Turkson J, Jove R. 2005. Mechanisms of disease: Insights into the emerging role of signal transducers and activators of transcription in cancer. Nat Clin Pract Oncol 2:315-324.
7. Hruban RH, Iacobuzio-Donahue C, Wilentz RE, Goggins M, Kern SE. 2001. Molecular pathology of pancreatic cancer. Cancer J 7:251-258.
8. Jaffee EM, Hruban RH, Canto M, Kern SE. 2002. Focus on pancreas cancer. Cancer Cell 2:25-28.
9. Li D, Xie K, Wolff R, Abbruzzese JL. 2004. Pancreatic cancer. Lancet 363:1049-1057.
10. Liu L, Cao Y, Chen C, Zhang X, McNabola A, Wilkie D, Wilhelm S, Lynch M, Carter C. 2006. Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. Cancer Res 66:11851-11858.
11. Panka DJ, Wang W, Atkins MB, Mier JW. 2006. The Raf inhibitor BAY 43-9006 (Sorafenib) induces caspase-independent apoptosis in melanoma cells. Cancer Res 66:1611-1619.
12. Plastaras JP, Kim SH, Liu YY, Dicker DT, Dorsey JF, McDonough J, Cerniglia G, Rajendran RR, Gupta A, Rustgi AK, Diehl JA, Smith CD, Flaherty KT, El-Deiry WS. 2007. Cell cycle dependent and schedule-dependent antitumor effects of sorafenib combined with radiation. Cancer Res 67:9443-9454.
13. Qiu Z, Huang C, Sun J, Qiu W, Zhang J, Li H, Jiang T, Huang K, Cao J. 2007. RNA interference-mediated signal transducers and activators of transcription 3 gene silencing inhibits invasion and metastasis of human pancreatic cancer cells. Cancer Sci 98:1099-1106.
14. Rahmani M, Davis EM, Bauer C, Dent P, Grant S. 2005. Apoptosis induced by the kinase inhibitor BAY 43-9006 in human leukemia cells involves down-regulation of Mcl-1 through inhibition of translation. J Biol Chem 280:35217-35227.
15. Rahmani M, Davis EM, Crabtree TR, Habibi JR, Nguyen TK, Dent P, Grant S. 2007. The kinase inhibitor sorafenib induces cell death through a process involving induction of endoplasmic reticulum stress. Mol Cell Biol 27:5499-5513.
16. Scholz A, Heinze S, Detjen KM, Peters M, Welzel M, Hauff P, Schirner M, Wiedenmann B, Rosewicz S. 2003. Activated signal transducer and activator of transcription 3 (STAT3) supports the malignant phenotype of human pancreatic cancer. Gastroenterology 125:891-905.
17. Skehan P, Storeng R, Scudiero D, Monks A, McMahon J, Vistica D, Warren JT, Bokesch H, Kenney S, Boyd MR. 1990. New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst 82:1107-1112.
18. Sridhar SS, Hedley D, Siu LL. 2005. Raf kinase as a target for anticancer therapeutics. Mol Cancer Ther 4:677-685.
19. Strumberg D, Clark JW, Awada A, Moore MJ, Richly H, Hendlisz A, Hirte HW, Eder JP, Lenz HJ, Schwartz B. 2007. Safety, pharmacokinetics, and preliminary antitumor activity of sorafenib: A review of four phase I trials in patients with advanced refractory solid tumors. Oncologist 12:426-437.
20. Wei D, Le X, Zheng L, Wang L, Frey JA, Gao AC, Peng Z, Huang S, Xiong HQ, Abbruzzese JL, Xie K. 2003. Stat3 activation regulates the expression of vascular endothelial growth factor and human pancreatic cancer angiogenesis and metastasis. Oncogene 22:319-329.
21. Wilhelm SM, Carter C, Tang L, Wilkie D, McNabola A, Rong H, Chen C, Zhang X, Vincent P, McHugh M, Cao Y, Shujath J, Gawlak S, Eveleigh D, Rowley B, Liu L, Adnane L, Lynch M, Auclair D, Taylor I, Gedrich R, Voznesensky A, Riedl B, Post LE, Bollag G, Trail PA. 2004. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 64:7099-7109.
22. Wilhelm SM, Adnane L, Newell P, Villanueva A, Llovet JM, Lynch M. 2008. Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling. Mol Cancer Ther 7:3129-3140.
23. Yoon JH, Werneburg NW, Higuchi H, Canbay AE, Kaufmann SH, Akgul C, Edwards SW, Gores GJ. 2002. Bile acids inhibit Mcl-1 protein turnover via an epidermal growth factor receptor/Raf-1-dependent mechanism. Cancer Res 62:6500-6505.
24. Yu C, Bruzek LM, Meng XW, Gores GJ, Carter CA, Kaufmann SH, Adjei AA. 2005. The role of Mcl-1 downregulation in the proapoptotic activity of the multikinase inhibitor BAY 43-9006. Oncogene 24:6861-6869.
25. Zhang H, Zhang J, Wei H, Tian Z. 2007. STAT3-decoy oligodeoxynucleotide inhibits the growth of human lung cancer via down-regulating its target genes. Oncol Rep 17:1377-1382.
26. Zhang W, Konopleva M, Ruvolo VR, McQueen T, Evans RL, Bornmann WG, McCubrey J, Cortes J, Andreeff M. 2008. Sorafenib induces apoptosis of AML cells via Bim-mediated activation of the intrinsic apoptotic pathway. Leukemia 22:808-818.